Table 2.
HR for HCC.
| Cohort | PS matched cohort | |||||||
|---|---|---|---|---|---|---|---|---|
| Tenofovir (ref: Entecavir) | Tenofovir (ref: Entecavir) | |||||||
| HR | 95% CI | P-value | HR | 95% CI | P-value | |||
| Crude model | 0.74 | 0.59 | 0.92 | 0.007 | 0.82 | 0.64 | 1.04 | 0.102 |
| Full model* | 0.89 | 0.71 | 1.12 | 0.315 | 0.87 | 0.69 | 1.11 | 0.274 |
| Main model** | 0.82 | 0.66 | 1.02 | 0.078 | 0.83 | 0.65 | 1.06 | 0.129 |
| IPTW | 0.86 | 0.69 | 1.06 | 0.149 | ||||
| Additional covariates | ||||||||
| Main model + APRI | 0.82 | 0.66 | 1.02 | 0.076 | 0.83 | 0.65 | 1.06 | 0.133 |
| Main model + FIB4 | 0.83 | 0.67 | 1.04 | 0.106 | 0.83 | 0.65 | 1.05 | 0.123 |
| Main model + CTP | 0.83 | 0.66 | 1.03 | 0.091 | 0.83 | 0.65 | 1.06 | 0.130 |
| Main model + AFP | 0.82 | 0.66 | 1.03 | 0.083 | 0.83 | 0.65 | 1.06 | 0.137 |
| Main model + CCI | 0.81 | 0.65 | 1.01 | 0.065 | 0.84 | 0.66 | 1.06 | 0.145 |
| Main model + Prior NA+ use | 0.86 | 0.69 | 1.08 | 0.189 | 0.85 | 0.66 | 1.09 | 0.193 |
| Subgroup analysis*** | ||||||||
| Sex | ||||||||
| Female | 0.68 | 0.40 | 1.14 | 0.145 | 0.72 | 0.41 | 1.26 | 0.246 |
| Male | 0.86 | 0.67 | 1.10 | 0.216 | 0.85 | 0.65 | 1.12 | 0.248 |
| Age, y/o | ||||||||
| ≤ 50 | 0.74 | 0.48 | 1.14 | 0.167 | 0.79 | 0.48 | 1.30 | 0.358 |
| > 50 | 0.84 | 0.65 | 1.09 | 0.187 | 0.86 | 0.65 | 1.13 | 0.271 |
| DM | ||||||||
| No | 0.83 | 0.64 | 1.07 | 0.141 | 0.84 | 0.64 | 1.11 | 0.218 |
| Yes | 0.80 | 0.51 | 1.28 | 0.352 | 0.78 | 0.48 | 1.28 | 0.328 |
| Liver cirrhosis | ||||||||
| No | 0.95 | 0.60 | 1.48 | 0.811 | 1.08 | 0.66 | 1.76 | 0.775 |
| Yes | 0.78 | 0.61 | 1.01 | 0.061 | 0.77 | 0.58 | 1.01 | 0.060 |
| Prior NA | ||||||||
| No | 0.78 | 0.60 | 1.01 | 0.054 | 0.79 | 0.60 | 1.04 | 0.095 |
| Yes | 1.25 | 0.74 | 2.11 | 0.406 | 1.10 | 0.61 | 2.01 | 0.748 |
| Stratified cDDD | ||||||||
| cDDDs ≤ 1095 | 1.03 | 0.82 | 1.31 | 0.791 | 1.07 | 0.83 | 1.39 | 0.588 |
| cDDDs > 1095 | 0.72 | 0.36 | 1.43 | 0.342 | 0.59 | 0.28 | 1.25 | 0.170 |
| CTP score | ||||||||
| A | 0.92 | 0.72 | 1.18 | 0.530 | 0.91 | 0.70 | 1.19 | 0.498 |
| B/C | 0.51 | 0.29 | 0.89 | 0.018 | 0.54 | 0.30 | 0.98 | 0.043 |
PS propensity score, HR hazard ratio, CT confidence interval, IPTW inverse probability treatment weighting, APRI AST to platelet ratio index, FIB-4 fibrosis index based on 4 factors, CTP Child–Turcotte–Pugh, AFP alpha-fetoprotein, CCI Charlson comorbidity index, NA nucleos(t)ide analogue, DM diabetes mellitus.
*Full model is adjusted for age, sex, liver cirrhosis, DM, APRI, FIB4, CCI, CTP, AST, ALT, platelet, AFP, albumin, bilirubin and INR. **Main model is adjusted for age, sex, liver cirrhosis, DM. ***HRs were estimated by fitting the main model.
+lamivudine, telbivudine, adefovir.